Centessa Pharmaceuticals plc (CNTA)
NASDAQ: CNTA · Real-Time Price · USD
16.63
-0.12 (-0.72%)
At close: Feb 21, 2025, 4:00 PM
16.60
-0.03 (-0.18%)
After-hours: Feb 21, 2025, 7:47 PM EST
Centessa Pharmaceuticals Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Centessa Pharmaceuticals stock have an average target of 23, with a low estimate of 11 and a high estimate of 35. The average target predicts an increase of 38.30% from the current stock price of 16.63.
Analyst Consensus: Strong Buy
* Price targets were last updated on Sep 19, 2024.
Analyst Ratings
The average analyst rating for Centessa Pharmaceuticals stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 4 | 4 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Strong Buy Reiterates n/a | Strong Buy | Reiterates | n/a | n/a | Feb 10, 2025 |
| TD Cowen | TD Cowen | Strong Buy Initiates n/a | Strong Buy | Initiates | n/a | n/a | Jan 7, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $24 → $28 | Strong Buy | Maintains | $24 → $28 | +68.37% | Nov 15, 2024 |
| Morgan Stanley | Morgan Stanley | Hold → Buy Upgrades $11 → $26 | Hold → Buy | Upgrades | $11 → $26 | +56.34% | Sep 19, 2024 |
| B. Riley Securities | B. Riley Securities | Strong Buy Initiates $33 | Strong Buy | Initiates | $33 | +98.44% | Sep 19, 2024 |
Financial Forecast
Revenue This Year
n/a
from 6.85M
Revenue Next Year
n/a
EPS This Year
-1.55
from -1.57
EPS Next Year
-1.59
from -1.55
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | 19.8M | |||
| Avg | n/a | n/a | 3.2M | |||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -1.47 | -1.14 | -1.06 | |||
| Avg | -1.55 | -1.59 | -1.68 | |||
| Low | -1.64 | -1.90 | -1.93 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.